Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of VCT220 in Overweight/Obese Subjects
NCT06569355Phase 2Completed
- Sponsor
- Vincentage Pharma Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VCT220 in obesity, Overweight, sponsored by Vincentage Pharma Co., Ltd.. Started Dec 2023; status: completed.
02
Drugs
VCT220
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06569355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569355.